middle.news
Orthocell’s Remplir™ Posts Near 90% Success in Expanded Nerve Repair Study
9:34am on Tuesday 28th of April, 2026 AEST
•
Healthcare
Read Story
Orthocell’s Remplir™ Posts Near 90% Success in Expanded Nerve Repair Study
9:34am on Tuesday 28th of April, 2026 AEST
Key Points
89.7% overall treatment success rate in 78 nerve procedures
90.3% success in motor nerve reconstruction with functional recovery
No adverse effects reported, confirming strong safety profile
Growing adoption in Australia, US, and first US military hospital use
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Orthocell (ASX:OCC)
OPEN ARTICLE